Patents by Inventor Rajendra Kumar-Singh

Rajendra Kumar-Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210052743
    Abstract: Methods and kits are provided for inhibiting inflammasome activation in cells of a subject or an inflammation-affected eye in a subject by administering to the subject a composition including a nucleotide sequence encoding a membrane independent CD59 protein operably linked to a promoter for expression and secretion of the membrane independent CD59 protein in the cells or the inflammation-affected eye, the composition inhibiting inflammasome activation.
    Type: Application
    Filed: February 11, 2019
    Publication date: February 25, 2021
    Inventors: Rajendra Kumar-Singh, Binit Kumar, Siobhan M. Cashman
  • Patent number: 10813977
    Abstract: Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: October 27, 2020
    Assignee: Trustees of Tufts College
    Inventors: Rajendra Kumar-Singh, Derek Leaderer, Siobhan Cashman
  • Publication number: 20200197484
    Abstract: Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.
    Type: Application
    Filed: June 14, 2019
    Publication date: June 25, 2020
    Inventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Kasmir Ramo
  • Publication number: 20190336499
    Abstract: The present disclosure relates to solid state forms of Selinexor, processes for preparation thereof and pharmaceutical compositions thereof.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Inventors: Anantha Rajmohan MUTHUSAMY, Sundara Lakshmi KANNIAH, Akash RAVI, Tonmoy Chitta DAS, Rajendra Popat CHEMATE, Anil Kumar SINGH, Yogesh Dhananjay WAGH
  • Patent number: 10351617
    Abstract: Methods, compositions and kits for regulating complement activity or treating a complement activity disorder in a subject using soluble, membrane-independent CD59 protein, methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: July 16, 2019
    Assignee: Trustees of Tufts College
    Inventors: Rajendra Kumar-Singh, Soibhan M. Cashman, Kasmir Ramo
  • Patent number: 10321101
    Abstract: A method and apparatus including providing a plurality of security systems, each detecting threats within a different respective secured geographic area and each reporting detected threats to a central monitoring station, a human user of a first of the plurality of security systems sending a notification to an authorized human user of a second of the plurality of security systems through the central monitoring station, the notification authorizing control of the first security system by the user of the second security system, in response to the notification, the central monitoring station forming a control connection between the first and second security systems and the user of the second security system controlling the first security system through a user interface of the second security system
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: June 11, 2019
    Assignee: ADEMCO INC.
    Inventors: Bharat Balaso Khot, Eric Oh, Ajay Partap Singh Chhokar, Karthikeyan Pollachi Duraiswamy, Kiran Kumar Guduguntla, Rajendra Kumar Venkata Alluri
  • Publication number: 20170209535
    Abstract: Compositions, methods and kits are provided for treating complement related disorders in a subject with protein in combination having protein fusions of at least two of a CD46 protein, a CD55 protein and a CD59 protein or with a recombinant chimeric protein having at least two of a CD46 protein, a CD55 protein and a CD59 protein or with nucleic acids encoding these proteins. The composition negatively modulates classical and alternative complement pathways thereby treating complement related disorder such as macular degeneration, age-related macular degeneration, diabetic retinopathy, inflammatory bowel disease, thyroiditis, cryoglobulinaemia, fetal loss, organ graft rejection, cancer, etc.
    Type: Application
    Filed: February 28, 2017
    Publication date: July 27, 2017
    Applicant: TUFTS UNIVERSITY
    Inventors: Rajendra Kumar-Singh, Derek Leaderer, Siobhan Cashman
  • Patent number: 8877896
    Abstract: Systems, compositions, methods, and kits for identifying potential therapeutic agents for treatment of complement based ocular diseases are provided herein. The methods and kits include a complement component 3 (C3) protein or derivative that is contacted to ocular cells or tissue. Another embodiment of the invention herein provides for diagnosis and/or prognosis of a complement-associated ocular disease. Compositions, methods and kits for regulating or treating a complement-related condition using at least one of CD46 protein, CD55 protein, and a recombinant chimeric soluble terminator of activated complement (STAC) protein or source of the STAC protein. The STAC protein includes an amino acid sequence including at least two of an amino acid sequence of a CD59 protein, an amino acid sequence derived from a CD46 protein, and an amino acid sequence derived from a CD55 protein, optionally further comprising a linker to connect amino acid sequences.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: November 4, 2014
    Assignee: Tufts University
    Inventors: Rajendra Kumar-Singh, Siobhan M. Cashman, John Harry Sweigard
  • Patent number: 8778886
    Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: July 15, 2014
    Assignee: Tufts University
    Inventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Sarah Parker Read
  • Patent number: 8324182
    Abstract: Methods and compositions for treating a subject having age-related macular degeneration (AMD), methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: December 4, 2012
    Assignee: Tufts University
    Inventors: Rajendra Kumar-Singh, Siobhan M Cashman, Kasmir Ramo
  • Publication number: 20110015136
    Abstract: Methods and compositions for treating a subject having age-related macular degeneration (AMD), methods of assaying human macular degeneration (MD), and methods and kits for assaying potential therapeutic agents for treatment of human MD are provided herein.
    Type: Application
    Filed: February 13, 2009
    Publication date: January 20, 2011
    Applicant: Tufts University
    Inventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Kasmir Ramo
  • Publication number: 20100209447
    Abstract: A peptide-POD with ability to penetrate and deliver fluorophores, siRNA, DNA and quantum dots to cells in culture and retinal and ocular tissues in vivo is provided herein. POD couples to adenovirus vectors, enhancing tropism for certain cells, potentially providing a safer and more efficacious method to deliver molecules to ocular and other tissues in vivo. POD constructs are therapeutic delivery vehicles for treating cells and tissues, including ocular cells and tissues suffering from retinal degeneration.
    Type: Application
    Filed: February 26, 2010
    Publication date: August 19, 2010
    Applicant: TUFTS UNIVERSITY
    Inventors: Rajendra Kumar-Singh, Siobhan M. Cashman, Sarah Parker Read
  • Publication number: 20100184838
    Abstract: Adenovirus (Ad) vectors are here provided for treatment of ocular tissues as are suitable methods to transduce photoreceptor (PR) cells, the tissue associated with degeneration. Expression from CMV or chicken beta actin (CBA) promoters in neural retina were compared, and CBA was found to be 173-fold more potent than CMV. Further, the RGD domain in Ad penton was found to play a key role in RPE tropism. Deletion of the RGD domain coupled with the CBA promoter permitted transgene expression in neural retina approximately 667-fold more efficiently than with prior Ad5 vectors. Use of Ad vectors in combination with a 4.7 kb rhodopsin promoter enabled transgene expression exclusively in photoreceptor cells in vivo.
    Type: Application
    Filed: April 11, 2008
    Publication date: July 22, 2010
    Applicant: TUFTS UNIVERSITY
    Inventors: Rajendra Kumar-Singh, Siobhan M. Cashman
  • Patent number: 6451596
    Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These “gutted” vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: September 17, 2002
    Assignee: Regents of the University of Michigan
    Inventors: Jeffrey S. Chamberlain, Andrea Amalfitano, Michael A. Hauser, Rajendra Kumar-Singh, Denis J. Hartigan-O'Connor
  • Patent number: 6083750
    Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
    Type: Grant
    Filed: February 5, 1999
    Date of Patent: July 4, 2000
    Assignee: Regents of the University of Michigan
    Inventors: Jeffrey S. Chamberlain, Rajendra Kumar-Singh
  • Patent number: 5994132
    Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These "gutted" vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.
    Type: Grant
    Filed: October 23, 1996
    Date of Patent: November 30, 1999
    Assignee: University of Michigan
    Inventors: Jeffrey S. Chamberlain, Rajendra Kumar-Singh
  • Patent number: D737825
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: September 1, 2015
    Inventors: Mandeep Kumar, Rajendra Kumar Singh, Vishaldeep Garg, Thilak Prakalathan